. "A semi-synthetic antibiotic that is a chlorinated derivative of oxacillin. [PubChem]"@en . . . "Cloxacillinum"@en . . . . . . . . . "By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cloxacillin interferes with an autolysin inhibitor."@en . . . . . . . . . . . . . . . "Cloxacillin"@en . "Enteric bacteria and other eubacteria"@en . " "@en . . "Used to treat infections caused by penicillinase-producing staphylococci, including pneumococci, group A beta-hemolytic streptococci, and penicillin G-sensitive and penicillin G-resistant staphylococci."@en . . . . . "CLOXACILLIN"@en . . "Cloxacilina"@en . . . . "95%"@en . . "(2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"@en . . . . . . "Doyle, F.P. and Nayler, J.H.C.; British Patent 905,778; September 12, 1962; assigned to Beecham Research Laboratories, Ltd. Doyle, F.P. and Nayler, J.H.C.; US. Patent 2,996,501; August 15, 1961. "@en . "6-(3-(O-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid"@en . "(3-(O-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin"@en . . . . "Cloxacilline"@en . . . . "Well absorbed from the gastrointestinal tract."@en . "approved"@en . . . "61-72-3"@en . . . . "Oral LD₅₀ in rat and mouse is 5000 mg/kg. Intravenous LD₅₀ in rat is 1660 mg/kg. Symptoms of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, and swelling of face, lips, tongue, or throat."@en . . . " "@en . . . . . . . . "Take on an empty stomach."@en . . .